WallStSmart

DexCom Inc (DXCM)vsMyomo Inc (MYO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 11591% more annual revenue ($4.82B vs $41.21M). DXCM leads profitability with a 19.3% profit margin vs -36.7%. DXCM earns a higher WallStSmart Score of 72/100 (B).

DXCM

Strong Buy

72

out of 100

Grade: B

Growth: 8.7Profit: 8.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 2.67

MYO

Avoid

28

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.0
Piotroski: 3/9Altman Z: -3.60
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DXCMUndervalued (+89.6%)

Margin of Safety

+89.6%

Fair Value

$656.95

Current Price

$74.54

$582.41 discount

UndervaluedFair: $656.95Overvalued

Intrinsic value data unavailable for MYO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DXCM4 strengths · Avg: 9.0/10
Return on EquityProfitability
31.5%10/10

Every $100 of equity generates 31 in profit

EPS GrowthGrowth
92.2%10/10

Earnings expanding 92.2% YoY

Operating MarginProfitability
21.4%8/10

Strong operational efficiency at 21.4%

Revenue GrowthGrowth
15.0%8/10

15.0% revenue growth

MYO0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

DXCM2 concerns · Avg: 4.0/10
P/E RatioValuation
32.9x4/10

Premium valuation, high expectations priced in

Price/BookValuation
9.7x4/10

Trading at 9.7x book value

MYO4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
2.9%4/10

2.9% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$40.96M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.

Bull Case : MYO

MYO has a balanced fundamental profile.

Bear Case : DXCM

The primary concerns for DXCM are P/E Ratio, Price/Book.

Bear Case : MYO

The primary concerns for MYO are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 2.11 is elevated, increasing financial risk.

Key Dynamics to Monitor

DXCM profiles as a mature stock while MYO is a turnaround play — different risk/reward profiles.

MYO carries more volatility with a beta of 1.46 — expect wider price swings.

DXCM is growing revenue faster at 15.0% — sustainability is the question.

DXCM generates stronger free cash flow (449M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (72/100 vs 28/100), backed by strong 19.3% margins and 15.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Myomo Inc

HEALTHCARE · MEDICAL DEVICES · USA

Myomo, Inc., a portable medical robotics company, designs, develops and produces myoelectric braces for people with neuromuscular disorders in the United States. The company is headquartered in Boston, Massachusetts.

Want to dig deeper into these stocks?